Ultragenyx Pharmaceutical Inc
RARE.O- Latest Trade
- trading higher44.14USD
- 0
- 0.00%
- As of Jan 27 2023. Values delayed up to 15 minutes
- Day Range
- -- - --
- 52-Week Range
- 33.36 - 85.53
- Previous Close
- 44.14
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 15.42
- Shares Out (Mil)
- 70.11
- Market Cap
- 3,042.59
- Forward P/E
- -4.44
- Dividend Yield
- 0.00
Key Statistics
1.73684211 mean rating - 19 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 8.86
- Price To Book (Quarterly)
- 6.49
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -49.49
- Return On Equity (TTM)
- -43.70
2021 (millions USD)
About Ultragenyx Pharmaceutical Inc (RARE.O)
Company Information
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Address
60 Leveroni CtNOVATO, CA
94949-5746
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Daniel G. Welch
- Independent Chairman of the Board
- Emil D. Kakkis
- President, Chief Executive Officer, Director
- Dennis Karl Huang
- Executive Vice President, Chief Technical Operations Officer and Gene Therapy Operations
- Karah Parschauer
- Executive Vice President, Chief Legal Officer, General Counsel
- Camille L. Bedrosian
- Chief Medical Officer, Executive Vice President
- Erik Harris
- Executive Vice President, Chief Commercial Officer
- Thomas Kassberg
- Chief Business Officer, Executive Vice President
- John R. Pinion
- Chief Quality Officer, Executive Vice President - Translational Sciences
- Deborah L. Dunsire
- Independent Director
- Lars G. Ekman
- Independent Director
- Matthew K. Fust
- Independent Director
- Michael A. Narachi
- Independent Director
- Amrit Ray
- Independent Director
- Corazon Dating Sanders
- Independent Director
- Shehnaaz Suliman
- Independent Director
Latest News
- MarketsU.S. RESEARCH ROUNDUP Api Group, Apria, Zynga
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Api Group, Apria and Zynga, on Tuesday.
- BusinessU.S. RESEARCH ROUNDUP Cognition Therapeutics, Mosaic, Shockwave Medical
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cognition Therapeutics, Mosaic and Shockwave Medical on Wednesday.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,929.10 | -- |
| Copper | 795.90 | 0.39% |
| Brent Crude Oil | 88.47 | 1.14% |
| CBOT Soybeans | 1,520.75 | 0.18% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,060.43 | 1.10% |
| Euro STOXX 50 | 4,179.22 | 0.13% |
| FTSE 100 | 7,773.89 | 0.16% |
| Nikkei 225 | 27,382.56 | 0.07% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes